IL-12

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

LeukemiaUlcerative Colitis (UC)Cryptosporidiosis

508 competitors in Leukemia

#DrugCompanyPhaseTrials

1

Trexall

Alnylam Pharmaceuticals

Phase 3

312

Rituxan

Roche

Phase 3

163

Cytoxan

BBaxter Healthcare Corporation

Phase 3

584

Fludara

Sanofi

Phase 3

115

Vepesid

AAvyxa

Phase 3

256

Decadron

AAspen Global Incorporated

Phase 3

247

Leukine

Sanofi

Phase 3

78

Oncovin

EEastern Cooperative Oncology Group

Phase 3

159

Busulfex

Akero Therapeutics

Phase 3

1310

Wellcovorin

EEastern Cooperative Oncology Group

Phase 3

12Show 32 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Immune Response4 trials

Safety of and Immune Response to an Investigational HIV-1 Vaccine With or Without Interleukin-12 (IL-12) in HIV-1 Infected Adults

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT01266616·62 enrolled

Evaluating the Safety of and Immune Response to HIV-MAG DNA Vaccine With or Without Plasmid IL-12 Adjuvant Delivered Intramuscularly Via Electroporation Followed by VSV-gag HIV Vaccine Boost in Healthy, HIV-Uninfected Adults

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT01578889·100 enrolled

Safety of and Immune Response to an HIV Preventive Vaccine (HIV-1 Gag DNA Alone or With IL-15 DNA) Given With or Without 2 Different Booster Vaccinations in HIV Uninfected Adults

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00115960·120 enrolled

Show 1 more trial

Safety of and Immune Response to the PENNVAX-B DNA Vaccine With and Without IL-12 in HIV-uninfected Adults

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00991354·48 enrolled

Immunogenicity2 trials

Safety and Immunogenicity of pDNA Vaccines Expressing HIV M Group p24^Gag Conserved Elements and/or p55^Gag, Administered With IL-12 pDNA

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT03181789·56 enrolled

Clinical Trial to Evaluate the Safety and Immunogenicity of Synthetic DNAs Encoding NP-GT8 and IL-12, With or Without a TLR-agonist-Adjuvanted HIV Env Trimer 4571 Boost, in Adults Without HIV

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT05781542·46 enrolled

Vaccine2 trials

Therapeutic Vaccine for HIV

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT01859325·33 enrolled

Study Evaluating Vaccine in Adults With HIV

Terminated·Pfizer·Phase 1·NCT00195312·91 enrolled

Effectiveness1 trial

Safety and Effectiveness of PENNVAX-B Vaccine Alone, With Il-12, or IL-15 in Healthy Adults

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00528489·120 enrolled

Cryptosporidiosis1 trial

Interleukin 12 (IL-12) for the Treatment of Cryptosporidiosis in AIDS Patients

Terminated·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT00057486·2 enrolled

Details

Drug Info

Related News